# China NMPA Drug Inspection - Anhui Bozhou Qiancao Pharmaceutical Co., Ltd. - amber

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-bozhou-qiancao-pharmaceutical-co-ltd/f84523c3-d43f-4e48-9096-4da00db56daa/
Source feed: China

> China NMPA drug inspection for Anhui Bozhou Qiancao Pharmaceutical Co., Ltd. published October 29, 2019. Drug: amber. The Shaanxi Provincial Drug Administration published an announcement on October 29, 2019, detailing the results of its e

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shaanxi Province Drug Quality Bulletin
- Company Name: Anhui Bozhou Qiancao Pharmaceutical Co., Ltd.
- Publication Date: 2019-10-29
- Drug Name: amber
- Inspection Finding: [Characteristics] [Identification] (Appearance, Identification) did not meet specifications.
- Action Taken: Relevant municipal (county, district) drug regulatory departments have taken necessary control measures for the units involved in the non-compliant drugs from this sampling inspection, and are currently investigating and dealing with them according to relevant laws and regulations.
- Summary: The Shaanxi Provincial Drug Administration published an announcement on October 29, 2019, detailing the results of its eighth drug quality inspection for the year. This inspection was part of an ongoing effort to strengthen drug oversight and ensure public medication safety across the province. The announcement highlighted four batches of drugs found to be non-compliant, necessitating immediate regulatory intervention.Key manufacturers involved in these non-compliant batches include Fujian Qiancao Pharmaceutical Co., Ltd., Anhui Bozhou Qiancao Guoyao Co., Ltd., Ningxian Kangshengyuan Pharmaceutical Co., Ltd., and Beijing Beizhongda Pharmaceutical Co., Ltd. The primary issues identified included deviations in critical quality attributes such as identification, content determination, physical properties (appearance), and general inspection parameters. Specific products affected were Puhuang (Raphanus sativus), Amber, Salt-processed Eucommia ulmoides, and Amomum villosum. The inspections were conducted against established regulatory frameworks, including the "Chinese Pharmacopoeia 2015 Edition, Part I" and the "Anhui Provincial Standards for Processing Traditional Chinese Medicine Pieces 2005 Edition." In response to these findings, relevant municipal and local drug regulatory departments have implemented necessary control measures for the implicated entities and initiated investigations to ensure compliance with applicable laws and regulations.

Company: https://www.globalkeysolutions.net/companies/anhui-bozhou-qiancao-pharmaceutical-co-ltd/f45fa03f-fd1b-4967-aa0d-5c8087bdd26c/